Bringing you the latest news, features and guidance advice from NICE NICE News
February 2012
Bringing you the latest news, features and guidance from NICE
New guidance
 
 

Greater options for patients with type 2 diabetes

 
 

NICE has approved the use of exenatide in triple therapy regimens for patients with type 2 diabetes, in latest guidance. Patients should be offered the drug if they are struggling to control their blood glucose levels or if they remain inadequate.

Read more  
 
 

Green light for earlier use of rheumatoid arthritis drug

 
 

Patients with rheumatoid arthritis can now be offered tocilizumab alongside other treatment options at an earlier stage. The drug is  recommended, in combination with methotrexate, for treating rheumatoid arthritis if treatment with disease-modifying anti-rheumatic drugs (DMARDS) has failed.

Read more  
 
Also this month
 
 

Improving access to NICE-approved drugs

NICE is to produce a best practice guide to help trusts develop local formularies, as part of a move to ensure that all patients in England have access to clinically and cost-effective drugs. This comes as latest findings reveal that not all local formularies are including all of NICE's technology appraisals.

 
  Read more  
 
Also this month
 
 

Making sure pregnant and breastfeeding women receive vitamin D

Certain groups of people are at particular risk of vitamin D deficiency, such as pregnant women and those who breastfeed. NICE has recognised this and produced public health guidance on maternal and child nutrition which recommends the use of vitamin D supplements to ensure they are getting all the nutrients they need.

 

 
  Read more  
 
Into practice
 
 

Clinical case scenarios

NICE has developed a number of new clinical case scenarios to help improve and assess users' knowledge of our guidance.  The case scenarios are an excellent educational resource that can be used for individual or group learning. This month, we have  case scenarios covering our guidance on adult and paediatric epilepsy, self harm and colorectal cancer.

 

 
  Read more  
 
New guidance
 
 

Let us know what you think about the draft recommendations for a clincial guideline on neutropenic sepsis - a potentially fatal complication of anti-cancer treatments such as chemotherapy. The guideline covers the prevention, identification and management of the complication.

Read more  
 
 

Should our public health guidance on needle and syringe programmes be updated? NICE reviews all public health guidance after 3 years to see whether the evidence base has moved on. Have your say on whether the guidance needs to incorporate new evidence.

Read more